Mouse anti Human CD5 FITC - CD20 PECatalog number: 0520
|Isotype||IgG2a (F)/IgG1 (PE)|
Bi-Testª Reagents (FITC/RPE)
Identification of human helper/inducer T cells expressing the 67,000 M.W. surface antigen, 85% peripheral blood lyymphocytes that form rosettes with sheep red blood cells (E+), and a small subset of B cells. Identicication of CD20 PE human B cells associated approximately 10% of peripheral blood lymphocytes.
Synonyms: CD5 FITC - CD20 PE
Immunogen: CD5=Derived from the hybridization of mouse NS-1/Ag4 myeloma cells with spleen cells of BALB/c mice immunized with human t-acute lymphoblastic leukemia (ALL) cells. CD20=Derived from the hybridization of mouse Sp2/0 myeloma cells with spleen cells from BALB/c mice immunized with the LB lymphoblastoid cell line.
Product Form: Bi-Test (FITC/RPE) Reagent
Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide and 0.2% carrier protein
Purification Method: Protein A/G Chromatography
Concentration: Titered for flow cytometry
PBMC: Add 10 µl of MAB/10^6 PBMC in 100 µl PBS. Mix gently and incubate for 15 minutes at 2° to 8°C. Wash twice with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. WHOLE BLOOD: Add 10 µl of MAB/100 µl of whole blood. Mix gently and incubate for 15 minutes at room temperature (20°C). Lyse the whole blood. Wash once with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. See instrument manufacturer’s instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.
Functional Analysis: Flow Cytometry Staining
Product should be stored at 4-8°C. DO NOT FREEZE
Product Stability: See expiration date on vial
Shipping Conditions: Room Temperature
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.
1. Anti-DNA Antibody Production by CD5+ and CD5- B Cells of Patients with Systemic Lupus Erythematosus. Suzuki N., Sakane T., Engleman EG, J. Clin. Invest. 1990 Ja;85(1):238-47. 2. Characteristics of CD11c+ CD5+ Chronic B cell Leukemias and the Identification of Novel Peripheral Blood B cell Subsets with Chronic Lymphoid Leukemia Immunophenotypes. Wormsley SB, Baird SM, Gadol N., Rai KR, Sobol RE, Blood 1990 July. 76(1):123-30. 3. Stimulation of CD5 Enhances Signal Transduction by the T cell Antigen Receptor. Imboden JB, June CH, McCutcheon MA, Ledbetter JA, J. Clin. Invest. 1990 Ja;85(1):130-4. 4. Surface Immunoglobulin Ligands and Cytokines Differentially Affect Proliferation and Antibody Production by Human CD5+ and CD5- B Lymphocytes. Nawata Y., Stall Am, Herzenberg LA, Eugui Em, Allison AC, Int. Immunol. 1990;2(7):603-14. 5. Evidence for Differential Responsiveness of Human CD5+ and CD5- B cell Subsets to T cell Independent Mitogens. Zupo S., Dono M., Azzoni L., Chiorazzi N., Ferrarini M., Eur. J. Immunol. 1991 Fe. 21(2):351-9. 6. In Vivo and In Vitro Expression of Myeloid Antigens on B-lineage Acute Lymphoblastic Leukemia Cells. Leukemia, 1991, Ja;5(1):19-25. Hara, J.; Kawa-Ha, K.; Yumura-Yagi, K.; Kurahashi, H.; Tawa, A.; Ishihara, S.; Inoue, M.; Murayama, N.; Okada, S. 7. Activation of Dense Human Tonsilar B Cells. Induction of C-Myc Gene Expression via Two Distinct Signal Transduction Pathways. Immunol., 1991, Feb;146(3):846-53. White, M. W.; McConnnell, F.; Shu, G.L.; Morris, D.R.; Clark, E.A. 8. Differential Effects of Low and High Concentrations of Interleukin 6 on Human B Cell. Eur J. Immunol. 1990 No. 20(11) :2389-93. Levy, Y.; Fermand, J.P; Broute, J.C. 9. Immunophenotypes in Classical B-cell Chronic Lymphocytic Leukemia. Correlation with Normal Cellular Counterpart and Clinical Findings. Cancer, 1990, Oct. 1;66(8):1738-42. Baldini, L.; Cro, L.; Cortelezzi, A.; Calori, R.; Nobili, L.; Maiolo, A.T.; Polli, E. E.
Database Name: UniProt
Accession Number: P06127, P11836
Safety Datasheet(s) for this product: